Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Actelion
|
| gptkbp:activities |
selective prostacyclin receptor agonist
|
| gptkbp:clinical_trial |
Phase III
approximately 100% |
| gptkbp:dosage_form |
film-coated tablet
|
| gptkbp:effective_date |
2015-12-21
|
| https://www.w3.org/2000/01/rdf-schema#label |
Uptravi
|
| gptkbp:ingredients |
gptkb:selexipag
C22 H25 N3 O4 S |
| gptkbp:is_atype_of |
C02 K X01
|
| gptkbp:is_used_for |
pulmonary arterial hypertension
|
| gptkbp:legal_issue |
prescription only
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Actelion_Pharmaceuticals
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:Japan gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:packaging |
gptkb:tablet
|
| gptkbp:side_effect |
headache
muscle pain nausea diarrhea jaw pain |